EX VIVO TREATMENT WITH ST1 IMMUNOTOXIN FOR PREVENT OF GRAFT VERSUS HOST DISEASE

使用 ST1 免疫毒素进行体外治疗以预防移植物抗宿主病

• 批准号: 3766620
• 负责人: JOSEPH ANTIN
• 金额: --
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766620
• 关键词: CD5 molecule; T lymphocyte; bone marrow transplantation; clinical trials; disease /disorder prevention /control; graft versus host disease; homologous transplantation; human subject; human therapy evaluation; immunoconjugates; immunotherapy; monoclonal antibody; ricin

This is a Phase I/II trial of the use of a monoclonal F(ab`)2 fragment conjugated to the A chain of ricin. The monoclonal antibody recognizes the CD5 cell surface protein. T cells that are CD5+ internalize the immunotoxin and are killed, thus reducing the number of infused T cells and reducing the risk of GvHD. We are assessing the therapy for rate of engraftment and rate of development of graft versus host disease.

这是使用单克隆f（ab`）2片段的I/II期试验 结合了ricin链。 单克隆抗体识别 CD5细胞表面蛋白。 CD5+内部化的T细胞 免疫毒素并被杀死，从而减少了注入的T细胞的数量 并降低了GVHD的风险。 我们正在评估治疗率 移植和宿主疾病的植入和发育率。